We recently published a list of 12 Undervalued Defensive Stocks for 2025. In this article, we are going to take a look at ...

GlaxoSmithKline (GSK – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Graham Parry from ...

GSK's consumer health spinout Haleon started trading on the London Stock Exchange this morning, making its debut with a price of 330 pence and a market valuation of around £31 billion ($37 billion).

Jefferies analyst Peter Welford maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The ...

News for GlaxoSmithKline Consumer Healthcare Ltd. Google.org Grants $1 Million to Karya for AI Upskilling in India Google.org awards USD 1 million to Karya, an Indian non-profit, to empower low-income ...

GlaxoSmithKline would consider buying Pfizer’s consumer health business – but only if the price is right, according to the company's chief executive. Emma Walmsley has also been busy shaking ...

We recently compiled a list of the 12 Cheapest Stocks with Biggest Upside Potential. In this article, we are going to take a ...

equal weightVarun Beverages Ltd.

The sale represents nearly 7.7% of issued share capital of Haleon, which was created by the merger of GSK and Pfizer's ...

Pfizer’s decision to offload $3.05 billion worth of shares in Haleon is a strategic move driven by shifting priorities in a ...

Pfizer will lower its stake in Haleon from 15 percent to about 7.3% by selling shares worth 2.50 billion pounds ($3.05 ...